Concepedia

Publication | Open Access

Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial

DOIFull Paper Access

118

Citations

32

References

2010

Year

David M. Asmuth, Robert L. Murphy, Susan L. Rosenkranz, Juan J.L. Lertora, Shyam Kottilil, Yoninah Cramer, Ellen S. Chan, Robert T. Schooley, Charles R. Rinaldo, Nathan M. Thielman,
The Journal of Infectious Diseases

Abstract

Pegylated interferon alfa-2a was well tolerated and exhibited statistically significant anti-HIV-1 activity in HIV-1-monoinfected patients. The anti-HIV-1 effect correlated with OAS protein levels (weeks 1 and 2) and IFIG induction levels (week 12) but not with pegylated interferon concentrations.

References

YearCitations

Page 1